GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Gubra AS (CHIX:GUBRAc) » Definitions » Accounts Payable

Gubra AS (CHIX:GUBRAC) Accounts Payable : kr16.2 Mil (As of Dec. 2024)


View and export this data going back to 2023. Start your Free Trial

What is Gubra AS Accounts Payable?

Gubra AS's Accounts Payable for the quarter that ended in Dec. 2024 was kr16.2 Mil.

Gubra AS's quarterly Accounts Payable increased from Dec. 2023 (kr11.4 Mil) to Jun. 2024 (kr14.8 Mil) and increased from Jun. 2024 (kr14.8 Mil) to Dec. 2024 (kr16.2 Mil).

Gubra AS's annual Accounts Payable increased from Dec. 2022 (kr10.6 Mil) to Dec. 2023 (kr11.4 Mil) and increased from Dec. 2023 (kr11.4 Mil) to Dec. 2024 (kr16.2 Mil).


Gubra AS Accounts Payable Historical Data

The historical data trend for Gubra AS's Accounts Payable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Gubra AS Accounts Payable Chart

Gubra AS Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Accounts Payable
Get a 7-Day Free Trial 4.47 5.38 10.59 11.41 16.17

Gubra AS Semi-Annual Data
Dec19 Dec20 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24
Accounts Payable Get a 7-Day Free Trial Premium Member Only 10.59 6.77 11.41 14.81 16.17

Gubra AS Accounts Payable Calculation

Accounts Payable represents any money that a company owes its suppliers for goods and services purchased on credit and is expected to pay within the next year or operating cycle.


Gubra AS Accounts Payable Related Terms

Thank you for viewing the detailed overview of Gubra AS's Accounts Payable provided by GuruFocus.com. Please click on the following links to see related term pages.


Gubra AS Business Description

Traded in Other Exchanges
Address
Horsholm Kongevej 11B, Horsholm, DNK, 2970
Gubra AS is a specialized preclinical CRO and biotech company focused on peptide-based drug discovery within metabolic and fibrotic diseases. The company has three segments: Pre-clinical contract research (CRO), which derives maximum revenue; Discovery & Partnerships (D&P) Segment; and Gubra Green Segment. It derives maximum revenue from Pre-clinical contract research (CRO) segment. Geographically, the company operates in Europe, North America and Other regions.

Gubra AS Headlines

No Headlines